Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience
- 1 October 1996
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (8) , 1280-1285
- https://doi.org/10.1038/bjc.1996.530
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumoursEuropean Journal Of Cancer, 1995
- Risk of Secondary Leukemia Following High Cumulative Doses of Etoposide During Chemotherapy for Testicular CancerJNCI Journal of the National Cancer Institute, 1995
- Vascular toxicity associated with chemotherapy for testicular cancerAnti-Cancer Drugs, 1994
- Management of malignant teratoma: does referral to a specialist unit matter?The Lancet, 1993
- Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor ProtocolsJNCI Journal of the National Cancer Institute, 1993
- Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing ChemotherapyJNCI Journal of the National Cancer Institute, 1993
- Etoposide, Cisplatin, Bleomycin, And Cyclophosphamide (Ecbc) As First-Line Chemotherapy for Poor-Risk Non-Seminomatous Germ Cell TumorsActa Oncologica, 1993
- Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Have new aggressive chemotherapy regimens improved results in advanced germ cell tumors?European Journal of Cancer and Clinical Oncology, 1986